SAN DIEGO, March 2, 2016 /PRNewswire/ -- Sequenom,
Inc., (NASDAQ: SQNM), a life sciences company committed to enabling
healthier lives through the development of innovative products and
services, announced the completion of an agreement with Anthem
BlueCross. The agreement provides in-network coverage for
Anthem's California customers for
Sequenom Laboratories' noninvasive prenatal tests in both high and
average risk pregnancies, beginning March
1, 2016.
"We are excited to be contracted with Anthem BlueCross," said
Dr. Dirk van den Boom, PhD,
President and CEO of Sequenom. "Our contract with Anthem is another
important step in our strategy to be an in-network provider and to
bring the benefits of noninvasive prenatal testing to as many
patients as possible, including women with average-risk
pregnancies."
About Sequenom
Sequenom, Inc. (NASDAQ: SQNM) is a pioneering genetic testing
company dedicated to women's health through the development of
innovative products and services. The Company serves patients
and physicians by providing early patient management
information. For more information, visit
www.sequenom.com.
About Sequenom Laboratories
Sequenom Laboratories, a CAP-accredited and CLIA-certified
molecular diagnostics laboratory, has developed a broad range of
laboratory tests, with a focus principally on prenatal care.
Branded under the names HerediT®, HerediT®
UNIVERSAL, MaterniT® GENOME, MaterniT21®
PLUS, NextView®, SensiGene® and
VisibiliT™, these molecular genetic laboratory-developed
tests provide early patient management information for
obstetricians, geneticists, and maternal fetal medicine
specialists. Sequenom Laboratories is changing the landscape in
genetic diagnostics using proprietary cutting edge technologies.
Visit www.laboratories.sequenom.com and follow @SequenomLabs.
SEQUENOM®, HerediT®,
MaterniT®, NextView®, SensiGene®,
VisibiliT™ and Sequenom Laboratories™ are
trademarks of Sequenom, Inc. All other trademarks and service marks
are the property of their respective owners.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995 including statements regarding the development of
innovative products and services and the ability to bring the
benefits of noninvasive prenatal testing to as many patients as
possible. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Risks
are described more fully in the Company's filings with
the Securities and Exchange Commission, including without
limitation the Company's most recent Annual Report on Form 10-K and
other documents subsequently filed with or furnished to
the Securities and Exchange Commission. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. The Company
undertakes no obligation to update such statements to reflect
events that occur or circumstances that exist after the date on
which they were made.
Logo - http://photos.prnewswire.com/prnh/20160225/337675LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/sequenom-announces-contract-with-anthem-bluecross-300229907.html
SOURCE Sequenom, Inc.